Clinical Trial

A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

The primary focus of this study is to evaluate the safety, tolerability, and efficacy of NGM282 on liver histology on adults between 18 and 75 years of age with histologically confirmed NASH diagnosis at 24 weeks versus placebo.

Information

Principal Investigator Rashmee Patil, MD
Co-PI
Sponsor NGM Biopharmaceuticals, Inc
Type of Trial Interventional